Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium is the major intracellular cation; it is essential for maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac and skeletal muscle, and normal renal function. Dextrose is a source of calories and fluid. Sodium chloride is an electrolyte replenisher.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous, 10-20 mEq/hour, not to exceed 40 mEq per dose or 200 mEq per day; rate not to exceed 1 mEq/kg/hour. Typical maintenance: 40-80 mEq/day.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Not applicable as potassium is not eliminated by first-order kinetics; clearance depends on renal function (GFR) and tubular handling. In patients with normal renal function, plasma potassium declines rapidly after IV infusion, with a distribution half-life of approximately 1 hour and an elimination half-life of 12-24 hours for excess potassium, but this is clinically not used. The terminal half-life is not defined due to physiological regulation.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Primarily renal (90% or more) as potassium ion via glomerular filtration and tubular secretion; minimal biliary/fecal (<5%).
Category C
Category A/B
Electrolyte
Electrolyte